PMC:7195088 / 1506-1810 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"20","span":{"begin":2,"end":10},"obj":"Species"},{"id":"21","span":{"begin":294,"end":302},"obj":"Species"},{"id":"23","span":{"begin":285,"end":293},"obj":"Disease"}],"attributes":[{"id":"A20","pred":"tao:has_database_id","subj":"20","obj":"Tax:9606"},{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Tax:9606"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"g patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T10","span":{"begin":285,"end":293},"obj":"Disease"}],"attributes":[{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"g patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T5","span":{"begin":118,"end":124},"obj":"Chemical"}],"attributes":[{"id":"A5","pred":"chebi_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/CHEBI_34922"}],"text":"g patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T16","span":{"begin":118,"end":303},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"g patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.\n"}